Caplight Directory>Companies>Larkspur Biosciences-preview>Larkspur-biosciences


Larkspur Biosciences

Larkspur Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.larkspur.bio

Last Round

Series A

May 23, 2023

Total Funding Raised

$35.5M

Momentum Score

25 /100

Company Overview

Larkspur Biosciences is a biotechnology company that develops immunotherapies aimed at enhancing cancer treatment by targeting the critical interaction between tumors and the immune system, thereby fostering a strong and lasting immune response in colorectal cancer and other malignancies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

precision immunotherapyimmuno-oncologyprotein degradersmall molecule degradercolorectal cancertargeted protein degradationTPDcold tumorscancer immunotherapyMSS CRCfirst-in-class therapyPIP4K2C degraderdrug developmentdrug discovery platformbiomarker-driven therapyML drug discoverysolid tumor therapypharma licensingoral cancer therapycheckpoint antibody

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Larkspur Biosciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Larkspur Biosciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMay 23, 2023
View all Funding Rounds

Larkspur Biosciences Investors

Notable investors and investment history

InvestorRounds
Creacion VenturesSeries A
Polaris Innovation FundSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2025

    Presented at the ACS Fall 2025 meeting.

  • Aug 21, 2025

    LRK-4189, a novel degrader for MSS colorectal cancer, was revealed at ACS Fall 2025.

View all signals

Larkspur Biosciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Larkspur Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Larkspur Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range19
Year Founded2020
Last FundingMay 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.